Pier Luigi Lollini

Summary

Country: Italy

Publications

  1. pmc Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice
    P Nanni
    Cancer Research Section, Department of Experimental Pathology, University of Bologna, Italy
    J Exp Med 194:1195-205. 2001
  2. pmc An integrated approach of immunogenomics and bioinformatics to identify new Tumor Associated Antigens (TAA) for mammary cancer immunological prevention
    Federica Cavallo
    Dept of Clinical and Biological Sciences, University of Torino, Az Ospedaliera S Luigi, Regione Gonzole 10, I 10043 Orbassano, Italy
    BMC Bioinformatics 6:S7. 2005
  3. ncbi request reprint Expression of functional CD40 on human osteosarcoma and Ewing's sarcoma cells
    P L Lollini
    Institute for Cancer Research, University of Bologna, Italy
    Clin Cancer Res 4:1843-9. 1998
  4. ncbi request reprint Cancer immunoprevention: tracking down persistent tumor antigens
    Pier Luigi Lollini
    Cancer Research Section, Dept of Experimental Pathology, University of Bologna, Viale Filopanti 22, Italy
    Trends Immunol 24:62-6. 2003
  5. ncbi request reprint Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice
    P L Lollini
    Institute for Cancer Research, University of Bologna, Italy
    Int J Cancer 77:937-41. 1998
  6. ncbi request reprint Expression of interleukin 15 (IL-15) in human rhabdomyosarcoma, osteosarcoma and Ewing's sarcoma
    P L Lollini
    Institute of Cancer Research, University of Bologna, Italy
    Int J Cancer 71:732-6. 1997
  7. ncbi request reprint Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine
    Carla De Giovanni
    Department of Experimental Pathology, University of Bologna, Bologna
    Cancer Res 64:4001-9. 2004
  8. ncbi request reprint Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice
    Patrizia Nanni
    Cancer Research Section, Department of Experimental Pathology, University of Bologna, I 40126 Bologna
    Cancer Res 63:2728-32. 2003
  9. pmc Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma
    Annalisa Astolfi
    Department of Experimental Pathology, Cancer Research Section, University of Bologna, Viale Filopanti 22, I 40126 Bologna, Italy
    Am J Pathol 166:1205-16. 2005
  10. doi request reprint In silico modeling and in vivo efficacy of cancer-preventive vaccinations
    Arianna Palladini
    Cancer Research Section, Department of Experimental Pathology, University of Bologna, Bologna, Italy
    Cancer Res 70:7755-63. 2010

Collaborators

Detail Information

Publications62

  1. pmc Combined allogeneic tumor cell vaccination and systemic interleukin 12 prevents mammary carcinogenesis in HER-2/neu transgenic mice
    P Nanni
    Cancer Research Section, Department of Experimental Pathology, University of Bologna, Italy
    J Exp Med 194:1195-205. 2001
    ..In conclusion, our data show that an allogeneic HER-2/neu-expressing cell vaccine combined with IL-12 systemic treatment can prevent the onset of genetically determined tumors...
  2. pmc An integrated approach of immunogenomics and bioinformatics to identify new Tumor Associated Antigens (TAA) for mammary cancer immunological prevention
    Federica Cavallo
    Dept of Clinical and Biological Sciences, University of Torino, Az Ospedaliera S Luigi, Regione Gonzole 10, I 10043 Orbassano, Italy
    BMC Bioinformatics 6:S7. 2005
    ..To address this question, a meta-analysis was performed on two transcription profile studies to identify a set of new TAA targets to be used instead of or in conjunction with Her2...
  3. ncbi request reprint Expression of functional CD40 on human osteosarcoma and Ewing's sarcoma cells
    P L Lollini
    Institute for Cancer Research, University of Bologna, Italy
    Clin Cancer Res 4:1843-9. 1998
    ..The results indicate that in human osteosarcoma and Ewing's sarcoma, CD40 is a functional receptor whose engagement can have opposite effects on tumor cell survival and malignancy...
  4. ncbi request reprint Cancer immunoprevention: tracking down persistent tumor antigens
    Pier Luigi Lollini
    Cancer Research Section, Dept of Experimental Pathology, University of Bologna, Viale Filopanti 22, Italy
    Trends Immunol 24:62-6. 2003
    ..Identifying such antigens will also provide new targets for cancer immunotherapy...
  5. ncbi request reprint Down regulation of major histocompatibility complex class I expression in mammary carcinoma of HER-2/neu transgenic mice
    P L Lollini
    Institute for Cancer Research, University of Bologna, Italy
    Int J Cancer 77:937-41. 1998
    ..Our results suggest that the immune response activated in vivo by HER-2/neu-positive tumors can lead to the emergence of escape variants characterized by a down-regulation of MHC class I products...
  6. ncbi request reprint Expression of interleukin 15 (IL-15) in human rhabdomyosarcoma, osteosarcoma and Ewing's sarcoma
    P L Lollini
    Institute of Cancer Research, University of Bologna, Italy
    Int J Cancer 71:732-6. 1997
    ..ELISA assays showed IL-15 release in a subset of rhabdomyosarcomas and osteosarcomas, but not in Ewing's sarcoma. The highest production of IL-15, in the picogram/ml range, was found in rhabdomyosarcoma cell lines RH30 and RD...
  7. ncbi request reprint Immunoprevention of HER-2/neu transgenic mammary carcinoma through an interleukin 12-engineered allogeneic cell vaccine
    Carla De Giovanni
    Department of Experimental Pathology, University of Bologna, Bologna
    Cancer Res 64:4001-9. 2004
    ..However, IL-12-engineered cell vaccine induced much lower circulating IL-12 and IFN-gamma, and therefore lower potential side effects and systemic toxicity...
  8. ncbi request reprint Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice
    Patrizia Nanni
    Cancer Research Section, Department of Experimental Pathology, University of Bologna, I 40126 Bologna
    Cancer Res 63:2728-32. 2003
    ..Our findings led to the hypothesis that the interaction between HER family genes and the p53 pathway might be involved in the origin of human rhabdomyosarcoma...
  9. pmc Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma
    Annalisa Astolfi
    Department of Experimental Pathology, Cancer Research Section, University of Bologna, Viale Filopanti 22, I 40126 Bologna, Italy
    Am J Pathol 166:1205-16. 2005
    ..This gene expression analysis reveals the immune events associated with prevention of tumor development and shows that HER-2/neu transgenic mice represent a good model of a poor-prognosis group of human breast tumors...
  10. doi request reprint In silico modeling and in vivo efficacy of cancer-preventive vaccinations
    Arianna Palladini
    Cancer Research Section, Department of Experimental Pathology, University of Bologna, Bologna, Italy
    Cancer Res 70:7755-63. 2010
    ..Our results show that an integrated in vivo-in silico approach could improve both mathematical and biological models of cancer immunoprevention...
  11. doi request reprint High metastatic efficiency of human sarcoma cells in Rag2/gammac double knockout mice provides a powerful test system for antimetastatic targeted therapy
    Patrizia Nanni
    Cancer Research Section, Department of Experimental Pathology, Viale Filopanti 22, University of Bologna, 40126 Bologna, Italy
    Eur J Cancer 46:659-68. 2010
    ..In conclusion, the Rag2(-/-);gammac(-/-) mouse model allowed the expression of human metastatic phenotypes inapparent in conventional immunodeficient mice and the preclinical testing of appropriate targeted therapies...
  12. ncbi request reprint Expression of a functional CCR7 chemokine receptor inhibits the post-intravasation steps of metastasis in malignant murine mammary cancer cells
    Stefania Croci
    Cancer Research Section, Department of Experimental Pathology, University of Bologna, I 40126 Bologna, Italy
    Oncol Rep 18:451-6. 2007
    ..When used as a prophylactic vaccine, CCR7-transduced cell vaccine succeeded in the long-term control of mammary tumorigenesis in 25% of the HER-2/neu transgenic females, suggesting an increased immunogenicity of CCR7-engineered cells...
  13. ncbi request reprint Antimetastatic activity of a preventive cancer vaccine
    Patrizia Nanni
    Section of Cancer Research, University of Bologna, Bologna, Italy
    Cancer Res 67:11037-44. 2007
    ....
  14. ncbi request reprint p185(neu) protein is required for tumor and anchorage-independent growth, not for cell proliferation of transgenic mammary carcinoma
    P Nanni
    Institute of Cancer Research, University of Bologna, Bologna, Italy
    Int J Cancer 87:186-94. 2000
    ....
  15. ncbi request reprint Immunoprevention of mammary carcinoma in HER-2/neu transgenic mice is IFN-gamma and B cell dependent
    Patrizia Nanni
    Cancer Research Section, Department of Experimental Pathology, University of Bologna, Bologna, Italy
    J Immunol 173:2288-96. 2004
    ..These findings show that inhibition of HER-2/neu carcinogenesis depends on cytokines and specific Abs, and that a highly effective vaccine can rescue Ab production even in B cell-deficient mice...
  16. ncbi request reprint Endothelin-3 production by human rhabdomyosarcoma: a possible new marker with a paracrine role
    Arianna Palladini
    Cancer Research Section, Department of Experimental Pathology, University of Bologna, Viale Filopanti 22, I 40126 Bologna, Italy
    Eur J Cancer 42:680-7. 2006
    ..Moreover ET-3 is present in plasma of mice bearing xenografts of human rhabdomyosarcoma cells, and may be potential new marker of the human rhabdomyosarcoma to be studied further...
  17. pmc Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus
    Patrizia Nanni
    Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
    PLoS Pathog 9:e1003155. 2013
    ..Brain metastases were also reduced. Cumulatively, upon i.p. administration the HER-2-redirected oncolytic HSV effectively reduced the growth of ovarian and breast carcinoma disseminated to the peritoneal cavity...
  18. ncbi request reprint Immunological prevention of a multigene cancer syndrome
    Stefania Croci
    Cancer Research Section, Department of Experimental Pathology, University of Bologna, Bologna, Italy
    Cancer Res 64:8428-34. 2004
    ..A highly effective vaccine against a single oncoprotein induced a powerful immune response that arrested multistep carcinogenesis in distinct target tissues...
  19. ncbi request reprint HER/erbB receptors as therapeutic targets of immunotoxins in human rhabdomyosarcoma cells
    Cinzia Ricci
    Section of Cancer Research, Department of Experimental Pathology, University of Bologna, Italy
    J Immunother 25:314-23. 2002
    ..The toxic activity of anti-EGF-R immunotoxin was also observed on rhabdomyosarcoma cells expressing low level of EGF-R. EGF-R could be a novel therapeutic target of immunotoxins in human rhabdomyosarcoma...
  20. ncbi request reprint Apc10.1: an ApcMin/+ intestinal cell line with retention of heterozygosity
    Carla De Giovanni
    Cancer Research Section, Department of Experimental Pathology, University of Bologna, Bologna, Italy
    Int J Cancer 109:200-6. 2004
    ..Supplementary material for this article can be found on the International Journal of Cancer website at http://www.interscience.wiley.com/jpages/0020-7136/suppmat/index.html...
  21. ncbi request reprint Immune prevention of mammary carcinogenesis in HER-2/neu transgenic mice: a microarray scenario
    Annalisa Astolfi
    Cancer Research Section, Department of Experimental Pathology, University of Bologna, Bologna, 40126, Italy
    Cancer Immunol Immunother 54:599-610. 2005
    ..Last, combination of the expression data with the protection results indicated that chronic vaccination is needed to maintain an active IFN-gamma-mediated response in the mammary gland...
  22. doi request reprint A multi-DNA preventive vaccine for p53/Neu-driven cancer syndrome
    C De Giovanni
    Cancer Research Section, Department of Experimental Pathology, Alma Mater Studiorum, University of Bologna, I 40126 Bologna, Italy
    Hum Gene Ther 20:453-64. 2009
    ..In conclusion, the Tri-DNA vaccine is as effective as Triplex cell vaccine, exploiting a more restricted immune stimulation...
  23. ncbi request reprint Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells
    Stefania Croci
    Cancer Research Section, Department of Experimental Pathology, University of Bologna, Bologna, Italy
    Cancer Res 64:1730-6. 2004
    ..CTGF emerges as a survival and differentiation factor and could be a new therapeutic target in human rhabdomyosarcoma...
  24. pmc Multiorgan metastasis of human HER-2+ breast cancer in Rag2-/-;Il2rg-/- mice and treatment with PI3K inhibitor
    Patrizia Nanni
    Section of Cancer Research, Department of Experimental Pathology, University of Bologna, Bologna, Italy
    PLoS ONE 7:e39626. 2012
    ....
  25. ncbi request reprint Cancer immunoprevention
    Pier Luigi Lollini
    Cancer Research Section, Department of Experimental Pathology, University of Bologna, Viale Filopanti 22, I 40126 Bologna, Italy
    Future Oncol 1:57-66. 2005
    ..The success obtained in preclinical studies suggests that cancer immunoprevention should progress to clinical testing...
  26. doi request reprint Tamoxifen combined to anti-HER-2/neu cell vaccine does not hamper cancer immunopreventive efficacy
    Carla De Giovanni
    Department of Experimental Pathology, Alma Mater Studiorum University of Bologna, Viale Filopanti 22, I 40126 Bologna, Italy
    Vaccine 27:2065-9. 2009
    ..These data suggest that tamoxifen could even have a positive impact on the efficacy of cancer immunoprevention...
  27. ncbi request reprint Expression of connective tissue growth factor (CTGF/CCN2) in a mouse model of rhabdomyosarcomagenesis
    Stefania Croci
    Department of Experimental Pathology, University of Bologna, Bologna, Italy
    Pathol Oncol Res 13:336-9. 2007
    ..Moreover, they expressed CCN2 protein at levels comparable to human rhabdomyosarcoma cells. Therefore BALBp53neu mice might be useful for the evaluation of the role played by CCN2 in rhabdomyosarcoma in vivo...
  28. pmc Uncoupling of growth inhibition and differentiation in dexamethasone-treated human rhabdomyosarcoma cells
    C De Giovanni
    Istituto di Cancerologia, University of Bologna, Italy
    Br J Cancer 67:674-9. 1993
    ..Therefore dexamethasone and N,N-dimethylformamide, both causing a decreased growth rate, showed opposing actions on myogenic differentiation and on c-myc proto-oncogene expression of human rhabdomyosarcoma cells...
  29. pmc Wild-type p53-mediated down-modulation of interleukin 15 and interleukin 15 receptors in human rhabdomyosarcoma cells
    C De Giovanni
    Cancer Research Institute, University of Bologna, Italy
    Br J Cancer 78:1541-6. 1998
    ..In conclusion, wild-type p53 transduction in human rhabdomyosarcoma cells induces the down-modulation of both IL-15 production and IL-15 receptor expression...
  30. doi request reprint Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer
    M A Pantaleo
    Institute of Hematology and Medical Oncology L A Seragnoli, Sant Orsola Malpighi Hospital, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
    Ann Oncol 20:213-26. 2009
    ..As a consequence, various critical questions are still open, and the implications of a translation in the clinical setting for EGFr imaging in cancer patients is discussed...
  31. doi request reprint Opposing control of rhabdomyosarcoma growth and differentiation by myogenin and interleukin 4
    Patrizia Nanni
    Section of Cancer Research, Department of Hematology and Oncological Sciences, University of Bologna, Bologna, Italy
    Mol Cancer Ther 8:754-61. 2009
    ..Strategies to increase myogenin expression and block IL-4 could simultaneously reduce growth and migration, and enhance terminal differentiation of rhabdomyosarcoma, thus contributing to the control of tumor growth and metastatic spread...
  32. pmc Induction of myogenic differentiation in human rhabdomyosarcoma cells by ionising radiation, N,N-dimethylformamide and their combination
    G Nicoletti
    Institute of Cancerology, University of Bologna, Italy
    Br J Cancer 65:519-22. 1992
    ....
  33. ncbi request reprint Production of stem cell factor and expression of c-kit in human rhabdomyosarcoma cells: lack of autocrine growth modulation
    L Landuzzi
    Institute of Cancer Research, University of Bologna, Italy
    Int J Cancer 78:441-5. 1998
    ..In conclusion, our data show that rhabdomyosarcoma cells produce consistent amounts of SCF but did not demonstrate autocrine growth modulation. SCF secretion may thus have a paracrine, rather than an autocrine activity in this tumor...
  34. ncbi request reprint An anti-apoptotic role for NGF receptors in human rhabdomyosarcoma
    A Astolfi
    Department of Experimental Pathology, Section of Cancer Research, University of Bologna, Viale Filopanti 22, I-40126, Bologna, Italy
    Eur J Cancer 37:1719-25. 2001
    ..These data suggest that the simultaneous presence of both high and low affinity NGF receptors engaged by endogenous or exogenous NGF might contribute to the escape from apoptosis exhibited by the rhabdomyosarcoma cells...
  35. ncbi request reprint Identification of new genes related to the myogenic differentiation arrest of human rhabdomyosarcoma cells
    A Astolfi
    Section of Cancer Research, Department of Experimental Pathology, University of Bologna, Bologna, Italy
    Gene 274:139-49. 2001
    ..These results identify a cluster of new genes related to the aberrant myogenic differentiation program of human rhabdomyosarcoma cells...
  36. ncbi request reprint Therapy of lung metastases through combined vaccination with carcinoma cells engineered to release IL-13 and IFN-gamma
    C De Giovanni
    Department of Experimental Pathology, University of Bologna, Italy
    Gene Ther 8:1698-704. 2001
    ..In conclusion, no antagonism but a synergistic and effective definitive cure stems from the combined vaccination with tumor cells engineered to release a Th1 and a Th2 cytokine...
  37. ncbi request reprint Immunoprevention of colorectal cancer: a future possibility?
    Pier Luigi Lollini
    Section of Cancer Research, Department of Experimental Pathology, University of Bologna, Viale Filopanti 22, I 40126 Bologna, Italy
    Gastroenterol Clin North Am 31:1001-14. 2002
    ..The design of a successful strategy for colorectal cancer will have to incorporate general concepts that have already been developed for dealing with other tumors, and intestine-specific immunologic strategies...
  38. ncbi request reprint Inhibition of prostate carcinogenesis by combined active immunoprophylaxis
    Carla De Giovanni
    Cancer Research Section, Department of Experimental Pathology, University of Bologna, Bologna, Italy
    Int J Cancer 121:88-94. 2007
    ....
  39. ncbi request reprint Expression of T cell receptor alpha gene (TCRA) in human rhabdomyosarcoma and other musculo-skeletal sarcomas
    Stefania Croci
    Cancer Research Section, Department of Experimental Pathology, University of Bologna, Viale Filopanti 22, I 40126 Bologna, Italy
    Gene 353:16-22. 2005
    ..TCRA ectopic transcripts/proteins negatively regulate rhabdomyosarcoma cell growth as suggested by TCRA gene expression downmodulation effects using a specific duplex small interfering RNA...
  40. ncbi request reprint Vaccines and other immunological approaches for cancer immunoprevention
    Pier Luigi Lollini
    Department of Hematology and Oncological Sciences, University of Bologna, Italy
    Curr Drug Targets 12:1957-73. 2011
    ..The development of agents like tamoxifen, which went from cancer therapy to chemoprevention, could be a model for the translation of cancer immunoprevention from mice to humans...
  41. doi request reprint Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER-2/neu oncogene-driven animal model system
    Stefania Croci
    Cancer Research Section, Department of Experimental Pathology, University of Bologna, Bologna, Italy
    Proteomics 10:3835-53. 2010
    ..Thus, the proteome-based approaches applied in the murine BALB-NeuT model might indeed provide candidates for immunoprevention strategies in breast cancer...
  42. ncbi request reprint New target antigens for cancer immunoprevention
    P L Lollini
    Cancer Research Section, Department of Experimental Pathology, University of Bologna, 40126 Bologna, Italy
    Curr Cancer Drug Targets 5:221-8. 2005
    ..Novel tumor antigens fulfilling both conditions will be crucial for the development of cancer immunoprevention and will provide new targets also for cancer immunotherapy...
  43. pmc In vitro differentiation of rhabdomyosarcomas induced by nickel or by Moloney murine sarcoma virus
    P Nanni
    Institute of Cancerology, University of Bologna, Italy
    Br J Cancer 63:736-42. 1991
    ..Myogenic differentiation ability was retained at a good level by nickel-induced tumours, whereas it was strongly impaired in MSV-induced tumours...
  44. pmc Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis
    Stefania Croci
    Laboratory of Immunology and Biology of Metastases, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Viale Filopanti 22, Bologna, 40126, Italy
    Breast Cancer Res 17:70. 2015
    ..Since IL-12 can induce the release of interleukin-15 (IL-15), in the present study we investigated the role played by IL-15 in HER2/neu driven mammary carcinogenesis and in its immunoprevention...
  45. doi request reprint Rethinking herpes simplex virus: the way to oncolytic agents
    Gabriella Campadelli-Fiume
    Department of Experimental Pathology, Section on Microbiology and Virology, Alma Mater Studiorum University of Bologna, Italy
    Rev Med Virol 21:213-26. 2011
    ..A strategy to generate o-HSVs fully retargeted to human epidermal growth factor receptor-2 (HER-2) or other cancer-specific surface receptors is detailed...
  46. ncbi request reprint Antitumor vaccines: is it possible to prevent a tumor?
    Pier Luigi Lollini
    Section of Cancer Research, Department of Experimental Pathology, University of Bologna, 40126 Bologna, Italy
    Cancer Immunol Immunother 51:409-16. 2002
    ..These issues can be addressed in preclinical studies in appropriate animal models...
  47. pmc Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases
    Valerio Leoni
    Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
    Oncotarget 6:34774-87. 2015
    ..The treatment significantly inhibited also breast cancer metastases to the brain in NSG mice, and reduced by more than one-half the metastatic burden in the brain...
  48. doi request reprint Preclinical vaccines against mammary carcinoma
    Pier Luigi Lollini
    Laboratory of Immunology and Biology of Metastasis, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Viale Filopanti 22, Bologna, Italy
    Expert Rev Vaccines 12:1449-63. 2013
    ..Translation to clinically effective vaccines will be fostered not only by new preclinical model systems, but also by the possibility to conduct veterinary vaccination trials in companion animals. ..
  49. pmc Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells
    Laura Menotti
    Department of Experimental Pathology, Section on Microbiology and Virology, University of Bologna, Via San Giacomo 12, 40126 Bologna, Italy
    Proc Natl Acad Sci U S A 106:9039-44. 2009
    ....
  50. pmc Preclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PET
    Maria Abbondanza Pantaleo
    Department of Hematology and Oncology Sciences L A Seragnoli, Sant Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    J Exp Clin Cancer Res 29:173. 2010
    ..We report a preclinical study on drug combinations in a xenograft model of GIST in which effects on tumor dimensions and metabolic activity were assessed by small animal PET imaging...
  51. ncbi request reprint The molecular basis of herpesviruses as oncolytic agents
    Laura Menotti
    Department of Experimental Pathology, University of Bologna, Bologna, Italy
    Curr Pharm Biotechnol 13:1795-803. 2012
    ..They will be reviewed along with the molecular bases of cancer specificity and the strategies for the enhancement of oncolytic potential of HSV recombinants...
  52. doi request reprint Molecular and cellular biology of rhabdomyosarcoma
    Carla De Giovanni
    Department of Experimental Pathology, Cancer Research Section, University of Bologna, Bologna, Italy
    Future Oncol 5:1449-75. 2009
    ..This review matches recent molecular data with biological features of rhabdomyosarcoma. Alterations in molecular pathways, animal models, cell of origin and potential new therapeutic targets are discussed...
  53. ncbi request reprint Interleukin 12 gene therapy of MHC-negative murine melanoma metastases
    P Nanni
    Institute for Cancer Research, University of Bologna, Italy
    Cancer Res 58:1225-30. 1998
    ..In conclusion, tumor therapy based on IL-12 gene transduction was effective on a MHC-negative metastatic tumor, suggesting a possible application to MHC-defective human neoplasms...
  54. ncbi request reprint Prevention of HER-2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12
    Patrizia Nanni
    Cancer Research Section, Department of Experimental Pathology, University of Bologna, Bologna, Italy
    Int J Cancer 105:384-9. 2003
    ..The addition of IL-12 to the tamoxifen treatment more than doubled mouse lifetime and did not exacerbate known side effects of tamoxifen...
  55. ncbi request reprint Vaccines for tumour prevention
    Pier Luigi Lollini
    Section of Cancer Research, Department of Experimental Pathology, University of Bologna, Italy
    Nat Rev Cancer 6:204-16. 2006
    ....
  56. doi request reprint Immunoprevention and immunotherapy of mammary carcinoma
    Pier Luigi Lollini
    Department of Hematology and Oncological Sciences, University of Bologna, Bologna, Italy
    Breast J 16:S39-41. 2010
    ..Preclinical results provide useful indications for the translation of cancer immunoprevention to humans, and useful hints for cancer immunotherapy...
  57. pmc The Promise of Preventive Cancer Vaccines
    Pier Luigi Lollini
    Department of Experimental Diagnostic and Specialty Medicine DIMES, University of Bologna, Viale Filopanti 22, Bologna 40126, Italy
    Vaccines (Basel) 3:467-89. 2015
    ..These considerations summed with the increased understanding of tumor antigens allow space for an optimistic view of the future. ..
  58. pmc Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET
    Maria A Pantaleo
    Department of Hematology and Oncological Sciences L A Serganoli, Sant Orsola Malpighi Hospital, University of Bologna, Via Massarenti 9, Bologna, Italy
    Mol Imaging Biol 12:616-25. 2010
    ....
  59. pmc Advances in preclinical therapeutics development using small animal imaging and molecular analyses: the gastrointestinal stromal tumors model
    M A Pantaleo
    Department of Hematology and Oncology Sciences L A Seragnoli, Sant Orsola Malpighi Hospital, University of Bologna, 40138, Bologna, Italy
    Clin Exp Med 9:199-205. 2009
    ..This approach of cancer research on GISTs is crucial and essential for innovative perspectives that could cross over to other types of cancer...
  60. pmc Discovery of cancer vaccination protocols with a genetic algorithm driving an agent based simulator
    Pier Luigi Lollini
    Sezione di Cancerologia, Dipartimento di Patologia Sperimentale, University of Bologna, Italy
    BMC Bioinformatics 7:352. 2006
    ..This is the first step toward a more general approach of biological or clinical constraints for the search of an effective vaccination schedule...
  61. ncbi request reprint Toward the definition of immunosuppressive regimens with antitumor activity
    F Casadio
    Section of Cancer Research, Department of Experimental Pathology, University of Bologna, Bologna, Italy
    Transplant Proc 37:2144-7. 2005
    ..Our data suggest that regimens containing rapamycin, mycophenolic acid, or leflunomide, which have both immunosuppressive and antitumor activities, should be preferred in transplant recipients to minimize the risk of tumors...
  62. ncbi request reprint Interleukin 6 gene-transfected mouse mammary adenocarcinoma: tumour cell growth and metastatic potential
    E Di Carlo
    Istituto di Patologia Umana e Medicina Sociale, Universita G D Annunzio, Italy
    J Pathol 182:76-85. 1997
    ..The differences in vascularization and macrophage infiltrate may underlie the observed differences between s.c. TSA-IL6 tumour growth with low spontaneous metastatic potential and the widespread growth of i.v. metastasis...